Celaid Therapeutics

Celaid Therapeutics is a clinical-stage Japanese biotechnology company focused on the development of next-generation cell therapies through the ex vivo expansion of hematopoietic stem cells (HSCs). The company utilizes a proprietary platform involving specific small molecules to efficiently expand high-quality HSCs, addressing the critical shortage of donor cells in conventional bone marrow and cord blood transplantations. Their lead program, CLD-101, aims to improve the success rates of cord blood transplants for patients with hematologic malignancies by accelerating engraftment and reducing complications. By optimizing the production of stem cells, Celaid Therapeutics seeks to make regenerative medicine more accessible and effective for patients with life-threatening blood disorders.